Sponsored Links
| TxCell Receives Approval For Extension Of Phase I/II Clinical Trial In Crohn's Disease |
 |
 |
 |
| Medical News - Crohn's | |||
|
TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the approval by AFSSAPS, the French regulatory agency, of its application to extend treatment of patients included in the Crohn's Disease phase I/II study (CATS1) with Ovasave, a type 1 regulatory T cell... Read more: Crohn's / IBD News From Medical News Today
|